Amylyx Pharmaceuticals Inc
AMLXHealthcare|Drug Manufacturers - Specialty & Generic|USA
$17.77
-0.60 (-3.29%)
Tangible Book
$2.46
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05021536 Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment | Amyotrophic Lateral Sclerosis | P3 | Active | 664 | RCT, Double-blind | AMX0035 |
| NCT06747468 Avexitide for Treatment of Post-Bariatric Hypoglycemia | Post Bariatric Hypoglycemia | P3 | Active | 75 | RCT, Double-blind | Avexitide |
| NCT05676034 AMX0035 in Adult Patients With Wolfram Syndrome | Wolfram Syndrome | P2 | Active | 12 | Open-label | AMX0035 |
| NCT06665165 AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | ALS | P1 | Recruiting | 48 | RCT, Double-blind | AMX0114 |
| NCT05619783 Extension Study Evaluating The Safety And Tolerability of AMX0035 | Amyotrophic Lateral Sclerosis | P3 | Completed | 352 | Open-label | AMX0035 |
| NCT04516096 A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2P3 | Completed | 28 | Open-label | AMX0035 |
| NCT06122662 AMX0035 and Progressive Supranuclear Palsy | Progressive Supranuclear Palsy, PSP | P2P3 | Completed | 139 | RCT, Double-blind | AMX0035 |
| NCT03488524 Open Label Extension Study of AMX0035 in Patients With ALS | Amyotrophic Lateral Sclerosis, ALS | P2 | Completed | 90 | Open-label | AMX0035 |
| NCT03533257 Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease | Alzheimer Disease | P2 | Completed | 95 | RCT, Double-blind | AMX0035, Placebo |
| NCT04987671 Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS | ALS | P1P2 | Unknown | 14 | Open-label | AMX0035 |
| NCT03127514 AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | P2 | Completed | 137 | RCT, Double-blind | AMX0035 |
| NCT07582874 An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia | Post-bariatric Hypoglycemia | AVAILABLE | — | — | Avexitide | |
| NCT05286372 An Intermediate Size Expanded Access Protocol of AMX0035 for ALS | Amyotrophic Lateral Sclerosis | APPROVED_FOR_MARKETING | — | — | AMX0035 |